Overview

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Status:
Completed

Trial end date:
2012-02-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the pharmacokinetics (how the drug is absorbed in the body, how it is distributed within the body and removed from the body over time), pharmacodynamics (how the study medication affects the body) and safety of rabeprazole after single and multiple daily administration in infants between the ages of 1 and 11 months, inclusive, with Gastroesophageal Reflux Disease (GERD).

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborator:

Eisai Inc.

Treatments:

Rabeprazole